Comparative proteomics of exosomes secreted by tumoral Jurkat T cells and normal human T cell blasts unravels a potential tumorigenic role for valosin-containing protein

Oncotarget

Volumn 7, Issue 20, 2016, Pages 29287-29305

  Bosque, Alberto ^a,d   Dietz, Lisa ^b   Gallego Lleyda, Ana ^a   Sanclemente, Manuel ^a   Iturralde, María ^a   Naval, Javier ^a   Alava, María Angeles ^a   Martínez Lostao, Luis ^a,c,e   Thierse, Hermann Josef ^b   Anel, Alberto ^a  

^a UNIVERSITY OF ZARAGOZA   (Spain)

^b UNIVERSITY OF HEIDELBERG   (Germany)

^c Instituto de Nanociencia y Materiales de Aragón   (Spain)

^d UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^e HOSPITAL CLÍNICO UNIVERSITARIO LOZANO BLESA   (Spain)

Author keywords

Apoptosis; Exosomes; Leukemia; Proteomics; T cells

Indexed keywords

ACTIN; CD18 ANTIGEN; CD2 ANTIGEN; CD38 ANTIGEN; CD48 ANTIGEN; CD5 ANTIGEN; CD6 ANTIGEN; CD97 ANTIGEN; CELLUBREVIN; DYNEIN ADENOSINE TRIPHOSPHATASE; FAS LIGAND; HERMES ANTIGEN; HETEROGENEOUS NUCLEAR RIBONUCLEOPROTEIN A2B1; INTERCELLULAR ADHESION MOLECULE 2; LUNG RESISTANCE PROTEIN; LYMPHOCYTE FUNCTION ASSOCIATED ANTIGEN 3; MEMBRANE COFACTOR PROTEIN; MEMBRANE PROTEIN; MESSENGER RNA; MINICHROMOSOME MAINTENANCE PROTEIN 7; N2,N4 DIBENZYLQUINAZOLINE 2,4 DIAMINE; PROTEIN INHIBITOR; RIBOSOME PROTEIN; RYANODINE RECEPTOR; SYNTAXIN 4; TUBULIN; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; UNCLASSIFIED DRUG; VALOSIN CONTAINING PROTEIN; VIMENTIN; VCP PROTEIN, HUMAN;

ARTICLE; CARCINOGENICITY; CELL DEATH; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG SENSITIVITY; ENDOPLASMIC RETICULUM; EXOSOME; HUMAN; HUMAN CELL; LEUKEMIA CELL; PROTEIN ANALYSIS; PROTEOMICS; T CELL LEUKEMIA; T LYMPHOCYTE; UBIQUITINATION; JURKAT CELL LINE; METABOLISM;

EXOSOMES; HUMANS; JURKAT CELLS; LEUKEMIA, T-CELL; PROTEOMICS; T-LYMPHOCYTES; VALOSIN CONTAINING PROTEIN;

EID: 84969802410     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.8678     Document Type: Article

References (71)

1. Schrier SL, Godin D, Gould RG, Swyryd B, Junga I and Seeger M. Characterization of microvesicles produced by shearing of human erythrocyte membranes. Biochim Biophys Acta. 1971; 233:26-36.
2. Harding CV, Heuser JE and Stahl H. Receptor-mediated endocytosis of transferrin and recycling of the transferrin receptor in rat reticulocytes. J Cell Biol. 1983; 97:329-339.
3. Pan BT and Johnstone RM. Fate of the transferrin receptor during maturation of sheep reticulocytes in vitro: selective externalization of the receptor. Cell. 1983; 33:967-978.
4. Johnstone RM and Ahn J. A common mechanism may be involved in the selective loss of plasma membrane functions during reticulocyte maturation. Biochim Biophys Acta. 1990; 49:S70-75.
5. Dalton AJ. Microvesicles and vesicles of multivesicular bodies verus "virus-like" particles. J Natl Cancer Inst. 1975; 54:1137-1148.
6. Der JE, Dixon WT, Jimbow K and Horikoshi T. A murine monoclonal antibody against a melanosomal component highly expressed in early stages and common to normal and neoplastic melanocytes. Br J Cancer. 1993; 67:47-57.
7. Peters PJ, Borst J, Oorschot V, Fukuda M, Krähenbühl O, Tschopp J, Slot JW and Geuze HJ. Cytotoxic T lymphocyte granules are secretory lysosomes, containing both perforin and granzymes. J Exp Med. 1991; 173:1099-1109.
8. Martínez-Lorenzo MJ, Anel A, Gamen S, Monleón I, Lasierra P, Larrad L, Piwñeiro A, Alava MA and Naval J. Activated human T cells release bioactive Fas ligand and APO2 ligand in microvesicles. J Immunol. 1999; 163:1274-1281.
9. Raposo G, Nijman HW, Stoorvogel W, Leijendekker R, Harding CV, Melief CJM and Geuze HJ. B lymphocytes secrete antigen-presenting vesicles. J Exp Med. 1996; 183:1161-1172.
10. Zitvogel L, Regnault A, Lozier A, Wolfers J, Flament C, Tenza D, Ricciardi-Castagnoli P, Raposo G and Amigorena S. Eradication of established murine tumors using a novel cell-free vaccine: dendritic cell-derived exosomes. Nature Med. 1998; 4:594-600.
11. Denzer K, van Eijk M, Kleijmeer MJ, Jakobson E, de Groot C and Geuze HJ. Follicular dendritic cells carry MHC class II-expressing microvesicles at their surface. J Immunol. 2000; 165:1259-1265.
12. Heijnen HF, Schiel AE, Fijnheer R, Geuze HJ and Sixma JJ. Activated platelets release two types of membrane vesicles: microvesicles by surface shedding and exosomes derived from exocytosis of multivesicular bodies and alphagranules. Blood. 1999; 94:3791-3799.
13. Skokos d, Le Panse S, Villa I, Rousselle JC, Peronet R, David B, Namame A and Mécheri S. Mast cell-dependent B and T lymphocyte activation is mediated by the secretion of immunologically active exosomes. J Immunol. 2001; 166:868-876.
14. Abrahams VM, Straszewski-Chavez SL, Guller S and Mor G. First trimester trophoblast cells secrete Fas ligand which induces immune cell apoptosis. Mol Human Reprod. 2004; 10:55-63.
15. van Niel G, Raposo G, Candalh C, Boussac M, Hershberg R, Cerf-Bensussan N and Heyman M. Intestinal epithelial cells secrete exosome-like vesicles. Gastroenterol. 2001; 121:337-349.
16. Nilsson BO, Jin M, Einarsson B, Persson BE and Ronquist G. Monoclonal antibodies against human prostasomes. Prostate. 1998; 35:178-184.
17. McKechnie NM, King BC, Fletcher E and Braun G. Fasligand is stored in secretory lysosomes of ocular barrier epithelia and released with microvesicles. Exp Eye Res. 2006; 83:304-314.
18. Baranov V, Yeung MM and Hammarström S. Expression of carcinoembrionic antigen and nonspecific cross-reacting 50 kDa antigen in human normal and cancerous colon mucosa: comparative ultrastructural study with monoclonal antibodies. Cancer Res. 1994; 54:3305-3314.
19. Oshima K, Aoki N, Kato T, Kitajima K and Matsuda T. Secretion of a peripheral membrane protein, MFG-E8, as a complex with membrane vesicles. A possible role in membrane secretion. Eur J Biochem. 2002; 269:1209-1218.
20. Pisitkun T, Shen RF and Knepper MA. Identification and proteomic profiling of exosomes in human urine. Proc Natl Acad Sci USA. 2004; 101:13368-13373.
21. Admyre C, Johansson SM, Qazi KR, Filén JJ, Lahesmaa R, Norman M, Neve EPA, Scheynius A and Gabrielson S. Exosomes with Immune Modulatory Features Are Present in Human Breast Milk. J Immunol. 2007; 179:1969-1978.
22. Simpson RJ, Lim JWE, Moritz RL and Mathivanan S. Exosomes: proteomic insights and diagnostic potential. Expert Rev Proteomics. 2009; 6:267-283.
23. Raposo G and Stoorvogel W. Extracellular vesicles: Exosomes, microvesicles, and friends. J Cell Biol. 2013; 200:373-383.
24. Gutiérrez-Vázquez C, Villarroya-Beltri C, Mittelbrunn M and Sánchez-Madrid F. Transfer of extracellular vesicles during immune cell-cell interactions. Immunol Rev. 2013; 25:125-142.
25. Monleón I, Martínez-Lorenzo MJ, Monteagudo L, Lasierra P, Taulés M, Iturralde M, Piñeiro A, Larrad L, Alava MA, Naval J and Anel A. Differential secretion of Fas ligandor APO2 ligand/TRAIL-carrying microvesicles during activation-induced death of human T cells. J Immunol. 2001; 167:6736-6744.
26. Alonso R, Mazzeo C, Rodriguez MC, Marsh M, Fraile-Ramos A, Calvo V, Avila-Flores A, Merida I and Izquierdo M. Diacylglycerol kinase a regulates the formation and polarisation of mature multivesicular bodies involved in the secretion of Fas ligand-containing exosomes in T lymphocytes. Cell Death Differ. 2011; 18:1161-1173.
27. Robbins PD and Morelli AE. Regulation of immune responses by extracellular vesicles. Nature Rev Immunol. 2014; 14:195-208.
28. Nikolov NP, Shimizu M, Cleland S, Balley D, Aoki J, Strom T, Schwartzberg PL, Candotti F and Siegel RM. Systemic autoimmunity and defective Fas ligand secretion in the absence of the Wiskott-Aldrich syndrome protein. Blood. 2010; 116:740-747.
29. Martín-Fernández JM, Cabanillas JA, Rivero-Carmena M, Lacasa E, Pardo J, Anel A, Ramírez-Duque PR, Merino F, Rodríguez-Gallego C and Regueiro JR. Herpesvirus saimiri-transformed CD8+ T cells as a tool to study Chediak-Higashi syndrome cytolytic lymphocytes. J Leukoc Biol. 2005; 77:661-668.
30. Martínez-Lorenzo MJ, Anel A, Sáez-Gutierrez B, Royo-Cañas M, Bosque A, Alava MA, Piñeiro A, Lasierra P, Asín-Ungría J and Larrad L. Rheumatoid synovial fluid T cells are sensitive to APO2L/TRAIL. Clin Immunol. 2007; 122:28-40.
31. Martinez-Lostao L, García-Alvarez F, Basáñez G, Alegre-Aguarón E, Desportes P, Larrad L, Naval J, Martínez-Lorenzo MJ and Anel A. Liposome-Bound APO2L/TRAIL Is an Effective Treatment in a Rabbit Model of Rheumatoid Arthritis. Arthrit Rheum. 2010; 62:2272-2282.
32. Lugini L, Ceccheti S, Huber V, Luciani F, Macchia G, Spadaro F, Paris L, Abalsamo L, Colone M, Molinari A and al. e. Immune surveillance properties of human NK cell-derived exosomes. J Immunol. 2013; 189:2833-2842.
33. Frangsmyr L, Baranov V, Nagaeva O, Stendahl U, Kjellberg L and Mincheva-Nilsson L. Cytoplasmic microvesicular form of Fas ligand in human early placenta: switching the tissue immune privilege hypothesis from cellular to vesicular level. Mol Human Reprod. 2005; 11:35-41.
34. André F, Schartz NEC, Movassagh M, Flament C, Pautier P, Morice P, Pomel C, Lhomme C, Escudier B, Le Chevalier T, Tusz T, Amigorena S, Raposo G, Angevin E and Zitvogel L. Malignant effusions and immunogenic tumour-derived exosomes. Lancet. 2002; 360:295-305.
35. Kim SH, Bianco N, Menon R, Lechman ER, Shufesky WJ, Morelli AE and Robbins PD. Exosomes Derived from Genetically Modified DC Expressing FasL Are Antiinflammatory and Immunosuppressive. Mol Ther. 2005; 13:289-300.
36. Huber V, Fais S, Iero M, Lugini L, Canese P, Squarcina P, Zaccheddu A, Colone M, Arancia G, Gentile M and al. e. Human colorectal cancer cells induce T-cell death through release of proapoptotic microvesicles: role in immune escape. Gastroenterol. 2005; 128:1796-1804.
37. Abrahams VM, Straszewski SL, Kamsteeg M, Hanczaruk B, Schwartz PE, Rutherford TJ and Mor G. Epithelial ovarian cancer cells secrete functional Fas ligand. Cancer Res. 2003; 63:5573-5581.
38. Taylor DD, Gerçel-Taylor C, Lyons KS, Stanson J and Whiteside TL. T-Cell Apoptosis and Suppression of T-Cell Receptor/CD3-z by Fas Ligand-Containing Membrane Vesicles Shed from Ovarian Tumors. Clin Cancer Res. 2003; 9:5113-5119.
39. Andreola G, Rivoltini L, Castelli C, Huber V, Perego P, Deho P, Squarcina P, Accornero P, Lozupone F, Lugini L and al. e. Induction of lymphocyte apoptosis by tumor cell secretion of FasL-bearing microvesicles. J Exp Med. 2002; 195:1303-1316.
40. Martínez-Lorenzo MJ, Anel A, Alava MA, Piñeiro A, Naval J, Lasierra P and Larrad L. The human melanoma cell line MelJuso secretes bioactive FasL and APO2L/TRAIL on the surface of microvesicles. Possible contribution to tumor counterattack. Exp Cell Res. 2004; 295:315-329.
41. Valenti R, Huber V, Iero M, Filipazzi P, Parmiani G and Rivoltini L. Tumor-released microvesicles as vehicles of immunosupression. Cancer Res. 2007; 67:2912-2915.
42. Wieckowski EU, Visus C, Szajnik M, Szczepanski MJ, Storkus WJ and Whiteside TL. Tumor-Derived Microvesicles Promote Regulatory T Cell Expansion and Induce Apoptosis in Tumor-Reactive Activated CD8+ T Lymphocytes. J Immunol. 2009; 183:3720-3730.
43. Wubbolts RW, Leckie RS, Veenhuizen PTM, Schwarzmann G, Moebius W, Hoernchemeyer J, Slot JW, Geuze HJ and Stoorvogel W. Proteomic and biochemical analyses of human B cell-derived exosomes: Potential implications for their function and multivesicular body formation. J Biol Chem. 2003; 278:10963-10972.
44. Théry C, Boussac M, Véron P, Ricciardi-Castagnoli P, Raposo G, Garin J and Amigorena S. Proteomic analysis of dendritic cell-derived exosomes: A secreted subcellular compartment distinct from apoptotic vesicles. J Immunol. 2001; 166:7309-7318.
45. Bard MP, Hegmans JP, Hemmes A, Luider TM, Willemsen R, Severijnen LA, van Meerbeeck JP, Burgers SA, Hoogsteden HC and Lambrecht BN. Proteomic analysis of exosomes isolated from malignant pleural effusions. Am J Respir Cell Mol Biol. 2004; 31:114-121.
46. Mathivanan S and Simpson RJ. ExoCarta: a compendium of exosomal proteins and RNA. Proteomics. 2009; 4997-5000.
47. Kalra H, Simpson RJ, Ji H, Aikawa E, Altevogt P, Askenase P, Bond VC, Borrás FE, Breakefield X, Budnik V and al. e. Vesiclepedia: a compendium for extracellular vesicles with continuous community annotation. PLos Biol. 2012; 10:e1001450.
48. Valadi H, Ekström K, Bossios A, Sjöstrand M, Lee JJ and Lötvall JO. Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells. Nature Cell Biol. 2007; 9:654-659.
49. Mittelbrunn M, Gutiérrez-Vázquez C, Villarroya-Beltri C, González S, Sánchez-Cabo F, González MA, Bernad A and Sánchez-Madrid F. Unidirectional transfer of microRNnAloaded exosomes from T cells to antigen-presenting cells. Nature Comm. 2011; 2:282.
50. Mittelbrunn M and Sánchez-Madrid F. Intercellular communication: diverse structures for exchange of genetic information. Nature Rev Mol Cell Biol. 2012; 13:328-335.
51. Blanchard N, Lankar D, Faure F, Regnault A, Dumont C, Raposo G and Hivroz C. TCR activation of human T cells induces the production of exosomes bearing the TCR/ CD3/z complex. J Immunol. 2002; 168:3235-3241.
52. Villarroya-Beltri C, Gutiérrez-Vázquez C, Sánchez-Cabo F, Pérez-Hernández D, Vázquez J, Martín-Cofreces N, Martínez-Herrera D, Pascual-Montano A, Mittelbrunn M and Sánchez-Madrid F. Sumoylated hnRNPA2B1 controls the sorting of miRNAs into exosomes through binding to specific motifs. Nature Commun. 2013; 4:2980.
53. Wang Q, Song C and Li CCH. Molecular perspectives on p97-VCP: progress in understanding its structure and diverse biological functions. J Struct Biol. 2004; 146:44-57.
54. Yamamoto S, Tomita Y, Hoshida Y, Takiguchi S, Fujiwara Y, Yasuda T, Yano M, Nakamori S, Sakon M, Monden M and Aozasa K. Expression Level of Valosin-Containing Protein Is Strongly Associated With Progression and Prognosis of Gastric Carcinoma. J Clin Oncol. 2003; 21:2537-2544.
55. Del Rey M, Ruiz-Contreras J, Bosque A, Calleja S, Gómez-Rial J, Roldán E, Morales P, Anel A, Paz-Artal E and Allende LM. A homozygous Fas ligand gene mutation in a patient causes a new type of autoimmune lymphoproliferative syndrome. Blood. 2006; 108:1306-1312.
56. Martínez-Lorenzo MJ, Alava MA, Anel A, Piñeiro A and Naval J. Release of preformed Fas ligand in soluble form is the major factor for activation-induced death of Jurkat T cells. Immunology. 1996; 89:511-517.
57. Martínez-Lorenzo MJ, Alava MA, Gamen S, Kim JK, Chuntharapai A, Piñeiro A, Naval J and Anel A. Involvement of APO2 ligand/TRAIL in activation-induced death of Jurkat and human peripheral blood T cells. Eur J Immunol. 1998; 28:2714-2725.
58. Stenqvist A, Nagaeva O, Baranov V and Mincheva-Nilsson L. Exosomes Secreted by Human Placenta Carry Functional Fas Ligand and TRAIL Molecules and Convey Apoptosis in Activated Immune Cells, Suggesting Exosome-Mediated Immune Privilege of the Fetus. J Immunol. 2013; 191:5515-5523.
59. Schmidt H, Gelhaus C, Nebendahl M, Lettau M, Lucius R, Leippe M, Kabelitz D and Janssen O. Effector Granules in Human T Lymphocytes: Proteomic Evidence for Two Distinct Species of Cytotoxic Effector Vesicles. J Proteome Res. 2011; 10:1603-1620.
60. Pérez-Hernández D, Gutiérrez-Vázquez C, Jorge I, López-Martín S, Ursa A, Sánchez-Madrid F, Vázquez J and Yáñez-Mó M. The Intracellular Interactome of Tetraspaninenriched Microdomains Reveals Their Function as Sorting Machineries toward Exosomes. J Biol Chem. 2013; 288:11649-11661.
61. Chou TF, Brown SJ, Minond D, Nordin BE, Li K, Jones AC, Chase P, Porubsky PR, Stoltz BM, Schoenen FJ and al. e. Reversible inhibitor of p97, DBeQ, impairs both ubiquitin-dependent and autophagic protein clearance pathways. Proc Natl Acad Sci USA. 2011; doi/10.1073/ pnas.1015312108.
62. Yi P, Higa A, Taouji S, Bexiga MG, Marza E, Arma D, Castain C, Le Bail B, Simpson JC, Rosenbaum J and al. e. Sorafenib-Mediated Targeting of the AAA+ ATPase p97/VCP Leads to Disruption of the Secretory Pathway, Endoplasmic Reticulum Stress, and Hepatocellular Cancer Cell Death. Mol Cancer Ther. 2012; 11:2610-2620.
63. Melo S, Luecke L, Kahlert C, Fernandez A, Gammon S, Kaye J, LeBleu V, Mittendorf E, Weitz J, Rahbari N and al. e. Glypican-1 identifies cancer exosomes and detects early pancreatic cancer. Nature. 2015; 523:177-182.
64. Peinado H, Aleckovic M, Lavotshkin S, Matei I, Costa-Silva B, Moreno-Bueno G, Hergueta-Redondo M, Williams C, García-Santos G, Nitadori-Hoshino A and al. e. Melanoma exosomes educate bone marrow progenitor cells toward a pro-metastatic phenotype through MET. Nature Med. 2012; 18:883-891.
65. Mantwill K, Köhler-Vargas N, Bernshausen A, Bieler A, Lage H, Kaszubiak A, Surowiak P, Dravits T, Treiber U, Hartung R and al. e. Inhibition of the Multidrug-Resistant Phenotype by Targeting YB-1 with a Conditionally Oncolytic Adenovirus: Implications for Combinatorial Treatment Regimen with Chemotherapeutic Agents. Cancer Res. 2006; 66:7915-8202.
66. Luo J. Oncogenic activity of MCM7 transforming cluster. World J Clin Oncol. 2011; 2:120-124.
67. Bosque A, Pardo J, Martínez-Lorenzo MJ, Iturralde M, Marzo I, Piñeiro A, Alava MA, Naval J and Anel A. Downregulation of normal human T cell blast activation: roles of APO2L/TRAIL, FasL and c-FLIP, Bim or Bcl-x isoform expression. J Leukoc Biol. 2005; 77:568-578.
68. Kobayashi T, Stang E, Fang KS, de Moerlosse P, Parton RG and Gruenberg J. A lipid associated with the antiphospholipid syndrome regulates endosome structure and function. Nature. 1998; 392:193-197.
69. Iturralde M, Pardo J, Lacasa E, Barrio G, Alava MA, Piñeiro A, Naval J and Anel A. Characterization of the lipolytic pathways that mediate free fatty acid release during Fas/ CD95-induced apoptosis. Apoptosis. 2005; 10:1369-1381.
70. Blum H, Beier H and Gross HJ. Improved silver staining of plant proteins, RNA and DNA in polyacrylamide gels. Electrophoresis. 1987; 8:93-99.
71. Diestre C, Martínez-Lorenzo MJ, Bosque A, Naval J, Larrad L and Anel A. Generation of rabbit antibodies against death ligands by cDNA immunization. J Immunol Meth. 2006; 317:12-20.